Clinical Trial

A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia

Study acronym: SMA-REAL
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this retrospective medical chart review is to describe the clinical outcomes, clinical characteristics, and demographics of patients with spinal muscular atrophy (SMA) type 1 treated with onasemnogene abeparvovec (OA) at a single clinical center in Saudi Arabia. The study will use secondary data collected from the electronic medical records of SMA type 1 patients.
Trial Details
NCT Number NCT07737756
Lead Sponsor Novartis Pharmaceuticals
Conditions Spinal Muscular Atrophy
Enrollment 6 participants
Start Date 2026-08-20
Primary Completion 2026-11-20 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-30